Immunotherapy: Open Access
Open Access

Laboratory of Virology, Institute of Infectious Agents, Laboratory associated with The National Reference Center for Respiratory Infection Viruses, Hospices Civils de Lyon, Lyon, France

Publications

• Case Report   
  Immunity to SARS-CoV-2 in a Dialyzed Patient who Developed COVID-19 Twenty Days after the Second Dose of BNT162b2 Vaccine: A Case Report
  Author(s): Sabrina Manni*, Laurène Lotte, Antonin Bal, Laurence Josset, Bruno Lina, Mary Anne Trabaud, Gregory Destras, Bruno Pozzetto, Martine Valette, Corinne Passeron, Barbara Seitz-Poslki, Audrey Sindt and Matteo Vassallo
  
  Introduction: End stage kidney disease (ESKD) and cancer have been identified as risk factors for severe and fatal cases of COVID-19, making vaccination in these patients a priority. Patients suffering from ESKD have a significantly weaker response to common vaccines than general population. However, humoral and cellular immune responses after two doses of RNA-based vaccine BNT162b2 (Pfizer–BioNTech) have been poorly explored in this vulnerable population. Case presentation: A 69-year-old male patient was followed for ESKD and myeloma treated with Daratumumab. He developed a severe SARS-CoV-2 pneumonia treated with oxygen supplementation and dexamethasone twenty days after two doses of BNT162b2 vaccine. Whole genome sequencing found that the virus belonged to the 20I/501Y.V1 clade. A serology draws eight days after t.. View More»
  DOI: 10.35248/2471-9552.22.08.192

  Abstract HTML PDF